CAR-T behind the CAR-T.

What’s new in CAR-T cell therapy? A new antigen receptor, that’s what. As opposed to the CD19 antigen engineered on the T cells of initial blockbuster drugs, CD22 antigens are the lynchpin of this novel phase 1 trial reporting an impressive remission rate of 70% among 58 patients with B-cell acute lymphoblastic leukemia refractory to CD19-targeted therapy. | Shah, J Clin Oncol 2020